
Illumina (ILMN) Stock Forecast & Price Target
Illumina (ILMN) Analyst Ratings
Bulls say
Illumina is well-positioned in the clinical sequencing market due to its dominant market share and strong financials. The company has a focused strategy for balancing pricing and profitability, while also investing in new products and potential subscription models. However, they may face challenges in the research market and China, which could impact their rating and stock price.
Bears say
Illumina is the market leader in next-generation sequencing, but faces potential headwinds from competitors such as Roche in the MRD field. While the company has multiple growth levers, there is uncertainty around whether they will actually reach growth rates above the mid-teens% as management has suggested. Additionally, Illumina faces sustainability concerns around product environmental footprint, human capital management, and data privacy/cybersecurity, which may negatively impact its reputation and profitability.
This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.
Illumina (ILMN) Analyst Forecast & Price Prediction
Start investing in Illumina (ILMN)
Order type
Buy in
Order amount
Est. shares
0 shares